As new therapies are introduced into clinical practice, clinical indications become defined, follow up protocols become refined and novel complications of the therapy are observed. The evolution and refinement of any new therapy was observed with EVAR and we are now seeing the same pattern with EVAS. In the third SAS meeting we will discuss the benefits that are evolving with EVAS, the aspects where more refinement of management is required and discuss management of complications.
The program of this third SAS meeting will encompass all of the key issues in this evolving field. Best practice in patient selection, graft implantation and post-operative imaging will be covered. Alongside treatment of non-ruptured infra-renal aneurysms, the newer applications of the use of EVAS with parallel grafts for the treatment of complex aneurysms will be discussed. In addition, the use of EVAS to repair failing EVAR will be debated alongside, the future generations of Nellix. There will be a focus on identification and management of late failure modes with regard to patient selection and revisional procedures.
As the world experience of EVAS increases, the scientific knowledge base has widened. A new feature of this year’s meeting is the inclusion of scientific abstracts that will detail the expanding knowledge base of EVAS and suggest avenues for future investigation.
Ian LOFTUS and Matt THOMPSON
This SAS 2017 edition is by invitation only